BUDESONIDE AND FORMOTEROL FUMARATE (BREYNA) Nursing Considerations

What is the generic name?

BUDESONIDE AND FORMOTEROL FUMARATE

What is the Trade Name for BUDESONIDE AND FORMOTEROL FUMARATE?

BREYNA

What are the Indications for BUDESONIDE AND FORMOTEROL FUMARATE?

• 1 INDICATIONS AND USAGE BREYNA is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: ‚Ä¢ Treatment of asthma in patients 6 years of age and older. ( 1.1 ) ‚Ä¢ Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: ‚Ä¢ Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma BREYNA is indicated for the treatment of asthma in patients 6 years of age and older. BREYNA should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta 2 -adrenergic agonist (LABA). Important Limitations of Use: ‚Ä¢ BREYNA is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Chronic Obstructive Pulmonary Disease BREYNA 160 mcg/4.5 mcg is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. BREYNA 160 mcg/4.5 mcg is also indicated to reduce exacerbations of COPD. BREYNA 160 mcg/4.5 mcg is the only strength indicated for the treatment of COPD. Important Limitations of Use: ‚Ä¢ BREYNA is NOT indicated for the relief of acute bronchospasm.

References: https://open.fda.gov/